ATEC earnings analysis
What we found in ATEC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Alphatec delivered $213.513 million of Q2 revenue, up 15% year over year and 11.2% sequentially, while gross margin expanded to 72.2% and operating margin improved to negative 0.9% from negative 7.1% a year earlier. Operating cash flow for the first half rose to $21.803 million, but cash fell to $118.7 million as investing outflows reached $42.609 million. The May refinancing extends the new JPM facilities to 2031, though the company retains approximately $684.6 million of disclosed borrowings and $63.3 million of notes due in August 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth remained double digit
- Q2 revenue increased $28.0 million, or 15%, year over year to $213.513 million. Revenue also rose $21.513 million, or 11.2%, from $192 million in Q1 2026, driven by a larger surgeon user base, new-product portfolio expansion, and technology adoption.
- Gross margin expanded about 260 bps
- Gross margin was 72.2% in Q2 2026, calculated from $213.513 million of revenue and $59.415 million of cost of sales, versus 69.6% a year earlier. Cost of sales rose only 5%, or $2.972 million, against 15% revenue growth.
- Operating margin approached breakeven
- Operating loss narrowed materially: operating margin improved to negative 0.9%, calculated from a $1.908 million operating loss, from negative 7.1% in Q2 2025. The sequential improvement was also substantial from negative 11.8% in Q1 2026.
- Operating cash flow more than doubled
- Six-month operating cash flow increased to $21.803 million from $10.509 million in the prior-year period. Management attributed the inflow to cash collections, partly offset by growth-related operating costs and inventory purchases.
- Debt maturities extended to 2031
- The company refinanced its credit facilities in May, borrowing $175.0 million under a term loan and $40.0 million under a revolver, both maturing May 1, 2031, and used proceeds plus cash to repay prior Braidwell and MidCap facilities.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Cash balance fell amid high investment
- Cash and cash equivalents declined $42.1 million to $118.7 million at June 30, 2026 from $160.8 million at December 31, 2025. Six-month investing cash use was $42.609 million, including surgical-instrument purchases and a $5.0 million note receivable.
- Leverage remains high; near-term notes mature
- Total disclosed borrowings were approximately $684.6 million at June 30, 2026: $175.0 million JPM term loan, $40.0 million JPM revolver, $63.3 million of 2026 Notes, $405.0 million of 2030 Notes, and $1.3 million of other debt. The $63.3 million 2026 Notes mature in August 2026.
- Interest and refinancing charges weigh on earnings
- The company recorded $23.717 million of Q2 other expense, including $10.964 million of net interest expense and an $11.883 million loss on debt extinguishment. Although operating loss narrowed to $1.908 million, these financing costs remain a significant drag on GAAP profitability.
- No material risk-factor updates
- No material changes were reported to risk factors from the 2025 Form 10-K. However, the filing notes a remaining $2.4 million minimum inventory purchase commitment through December 2026, adding a fixed procurement obligation.
What they reported.
What the company itself reported, taken out of the document.
- Gross margin
- 72.2%
- Operating margin
- -0.9%
What they said about what is next.
The 10-Q does not provide quantitative revenue or EPS guidance in MD&A. Quantitative FY2026 outlook was addressed in the separately filed earnings release rather than this quarterly report.
The filing reads better than the one before it.
What came before.
- 10-Q · May 5, 2026
- Alphatec Holdings, Inc. reported Q1 2026 results with total revenue of $192.1 million, missing estimates by 2.58%, while EPS was at $0.00, beating estimates of -$0.03. Overall, the company continues to focus on capital…
- 10-K · February 24, 2026
- Alphatec reported total revenue of $764.2 million for the year ended December 31, 2025, a 25% increase versus $611.6 million in 2024, driven by surgeon adoption and higher surgical volume. Margins and cash flow trended…
- 10-Q · May 1, 2025
- Alphatec reported Q1 revenue of $169.18M (up $30.703M or 22.2% vs $138.477M a year ago) with gross profit of $115.996M (68.6% margin) and an operating loss of $44.291M (−26.2% operating margin). Operating cash use…
- 10-Q · May 7, 2024
- Alphatec reported Q1 revenue of $138,477,000, up $29,367,000 or 26.9% versus Q1 2023 ($109,110,000), with gross profit rising to $97,351,000 (70.3% gross margin). Despite top-line and gross-margin improvement, operating…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ATEC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever